Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 16 de 16
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Liver Int ; 44(8): 1872-1885, 2024 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-38573034

RESUMEN

BACKGROUND & AIMS: There is a need to reduce the screen failure rate (SFR) in metabolic dysfunction-associated steatohepatitis (MASH) clinical trials (MASH+F2-3; MASH+F4) and identify people with high-risk MASH (MASH+F2-4) in clinical practice. We aimed to evaluate non-invasive tests (NITs) screening approaches for these target conditions. METHODS: This was an individual participant data meta-analysis for the performance of NITs against liver biopsy for MASH+F2-4, MASH+F2-3 and MASH+F4. Index tests were the FibroScan-AST (FAST) score, liver stiffness measured using vibration-controlled transient elastography (LSM-VCTE), the fibrosis-4 score (FIB-4) and the NAFLD fibrosis score (NFS). Area under the receiver operating characteristics curve (AUROC) and thresholds including those that achieved 34% SFR were reported. RESULTS: We included 2281 unique cases. The prevalence of MASH+F2-4, MASH+F2-3 and MASH+F4 was 31%, 24% and 7%, respectively. Area under the receiver operating characteristics curves for MASH+F2-4 were .78, .75, .68 and .57 for FAST, LSM-VCTE, FIB-4 and NFS. Area under the receiver operating characteristics curves for MASH+F2-3 were .73, .67, .60, .58 for FAST, LSM-VCTE, FIB-4 and NFS. Area under the receiver operating characteristics curves for MASH+F4 were .79, .84, .81, .76 for FAST, LSM-VCTE, FIB-4 and NFS. The sequential combination of FIB-4 and LSM-VCTE for the detection of MASH+F2-3 with threshold of .7 and 3.48, and 5.9 and 20 kPa achieved SFR of 67% and sensitivity of 60%, detecting 15 true positive cases from a theoretical group of 100 participants at the prevalence of 24%. CONCLUSIONS: Sequential combinations of NITs do not compromise diagnostic performance and may reduce resource utilisation through the need of fewer LSM-VCTE examinations.


Asunto(s)
Diagnóstico por Imagen de Elasticidad , Enfermedad del Hígado Graso no Alcohólico , Humanos , Diagnóstico por Imagen de Elasticidad/métodos , Enfermedad del Hígado Graso no Alcohólico/diagnóstico , Enfermedad del Hígado Graso no Alcohólico/diagnóstico por imagen , Curva ROC , Hígado/patología , Hígado/diagnóstico por imagen , Cirrosis Hepática/diagnóstico , Biopsia , Tamizaje Masivo/métodos
2.
Gut ; 71(5): 1006-1019, 2022 05.
Artículo en Inglés | MEDLINE | ID: mdl-34001645

RESUMEN

OBJECTIVE: Liver biopsy is still needed for fibrosis staging in many patients with non-alcoholic fatty liver disease. The aims of this study were to evaluate the individual diagnostic performance of liver stiffness measurement by vibration controlled transient elastography (LSM-VCTE), Fibrosis-4 Index (FIB-4) and NAFLD (non-alcoholic fatty liver disease) Fibrosis Score (NFS) and to derive diagnostic strategies that could reduce the need for liver biopsies. DESIGN: Individual patient data meta-analysis of studies evaluating LSM-VCTE against liver histology was conducted. FIB-4 and NFS were computed where possible. Sensitivity, specificity and area under the receiver operating curve (AUROC) were calculated. Biomarkers were assessed individually and in sequential combinations. RESULTS: Data were included from 37 primary studies (n=5735; 45% women; median age: 54 years; median body mass index: 30 kg/m2; 33% had type 2 diabetes; 30% had advanced fibrosis). AUROCs of individual LSM-VCTE, FIB-4 and NFS for advanced fibrosis were 0.85, 0.76 and 0.73. Sequential combination of FIB-4 cut-offs (<1.3; ≥2.67) followed by LSM-VCTE cut-offs (<8.0; ≥10.0 kPa) to rule-in or rule-out advanced fibrosis had sensitivity and specificity (95% CI) of 66% (63-68) and 86% (84-87) with 33% needing a biopsy to establish a final diagnosis. FIB-4 cut-offs (<1.3; ≥3.48) followed by LSM cut-offs (<8.0; ≥20.0 kPa) to rule out advanced fibrosis or rule in cirrhosis had a sensitivity of 38% (37-39) and specificity of 90% (89-91) with 19% needing biopsy. CONCLUSION: Sequential combinations of markers with a lower cut-off to rule-out advanced fibrosis and a higher cut-off to rule-in cirrhosis can reduce the need for liver biopsies.


Asunto(s)
Diabetes Mellitus Tipo 2 , Diagnóstico por Imagen de Elasticidad , Enfermedad del Hígado Graso no Alcohólico , Biomarcadores , Biopsia , Femenino , Fibrosis , Humanos , Hígado/diagnóstico por imagen , Hígado/patología , Cirrosis Hepática/diagnóstico , Cirrosis Hepática/patología , Masculino , Persona de Mediana Edad , Enfermedad del Hígado Graso no Alcohólico/complicaciones , Enfermedad del Hígado Graso no Alcohólico/diagnóstico , Enfermedad del Hígado Graso no Alcohólico/patología
3.
Radiology ; 305(3): 526-537, 2022 12.
Artículo en Inglés | MEDLINE | ID: mdl-36255312

RESUMEN

Nonalcoholic fatty liver disease (NAFLD) is believed to affect one-third of American adults. Noninvasive methods that enable detection and monitoring of NAFLD have the potential for great public health benefits. Because of its low cost, portability, and noninvasiveness, US is an attractive alternative to both biopsy and MRI in the assessment of liver steatosis. NAFLD is qualitatively associated with enhanced B-mode US echogenicity, but visual measures of B-mode echogenicity are negatively affected by interobserver variability. Alternatively, quantitative backscatter parameters, including the hepatorenal index and backscatter coefficient, are being investigated with the goal of improving US-based characterization of NAFLD. The American Institute of Ultrasound in Medicine and Radiological Society of North America Quantitative Imaging Biomarkers Alliance are working to standardize US acquisition protocols and data analysis methods to improve the diagnostic performance of the backscatter coefficient in liver fat assessment. This review article explains the science and clinical evidence underlying backscatter for liver fat assessment. Recommendations for data collection are discussed, with the aim of minimizing potential confounding effects associated with technical and biologic variables.


Asunto(s)
Enfermedad del Hígado Graso no Alcohólico , Adulto , Humanos , Enfermedad del Hígado Graso no Alcohólico/diagnóstico por imagen , Enfermedad del Hígado Graso no Alcohólico/patología , Estudios Prospectivos , Hígado/diagnóstico por imagen , Hígado/patología , Ultrasonografía/métodos , Imagen por Resonancia Magnética
4.
J Hepatol ; 75(4): 770-785, 2021 10.
Artículo en Inglés | MEDLINE | ID: mdl-33991635

RESUMEN

BACKGROUND AND AIMS: Vibration-controlled transient elastography (VCTE), point shear wave elastography (pSWE), 2-dimensional shear wave elastography (2DSWE), magnetic resonance elastography (MRE), and magnetic resonance imaging (MRI) have been proposed as non-invasive tests for patients with non-alcoholic fatty liver disease (NAFLD). This study evaluated their diagnostic accuracy for liver fibrosis and non-alcoholic steatohepatitis (NASH). METHODS: PubMED/MEDLINE, EMBASE and the Cochrane Library were searched for studies examining the diagnostic accuracy of these index tests, against histology as the reference standard, in adult patients with NAFLD. Two authors independently screened and assessed methodological quality of studies and extracted data. Summary estimates of sensitivity, specificity and area under the curve (sAUC) were calculated for fibrosis stages and NASH, using a random effects bivariate logit-normal model. RESULTS: We included 82 studies (14,609 patients). Meta-analysis for diagnosing fibrosis stages was possible in 53 VCTE, 11 MRE, 12 pSWE and 4 2DSWE studies, and for diagnosing NASH in 4 MRE studies. sAUC for diagnosis of significant fibrosis were: 0.83 for VCTE, 0.91 for MRE, 0.86 for pSWE and 0.75 for 2DSWE. sAUC for diagnosis of advanced fibrosis were: 0.85 for VCTE, 0.92 for MRE, 0.89 for pSWE and 0.72 for 2DSWE. sAUC for diagnosis of cirrhosis were: 0.89 for VCTE, 0.90 for MRE, 0.90 for pSWE and 0.88 for 2DSWE. MRE had sAUC of 0.83 for diagnosis of NASH. Three (4%) studies reported intention-to-diagnose analyses and 15 (18%) studies reported diagnostic accuracy against pre-specified cut-offs. CONCLUSIONS: When elastography index tests are acquired successfully, they have acceptable diagnostic accuracy for advanced fibrosis and cirrhosis. The potential clinical impact of these index tests cannot be assessed fully as intention-to-diagnose analyses and validation of pre-specified thresholds are lacking. LAY SUMMARY: Non-invasive tests that measure liver stiffness or use magnetic resonance imaging (MRI) have been suggested as alternatives to liver biopsy for assessing the severity of liver scarring (fibrosis) and fatty inflammation (steatohepatitis) in patients with non-alcoholic fatty liver disease (NAFLD). In this study, we summarise the results of previously published studies on how accurately these non-invasive tests can diagnose liver fibrosis and inflammation, using liver biopsy as the reference. We found that some techniques that measure liver stiffness had a good performance for the diagnosis of severe liver scarring.


Asunto(s)
Diagnóstico por Imagen de Elasticidad/normas , Imagen por Resonancia Magnética/normas , Enfermedad del Hígado Graso no Alcohólico/diagnóstico por imagen , Adulto , Área Bajo la Curva , Diagnóstico por Imagen de Elasticidad/métodos , Diagnóstico por Imagen de Elasticidad/estadística & datos numéricos , Humanos , Imagen por Resonancia Magnética/métodos , Imagen por Resonancia Magnética/estadística & datos numéricos , Enfermedad del Hígado Graso no Alcohólico/diagnóstico , Curva ROC
6.
Br J Clin Pharmacol ; 83(2): 326-338, 2017 02.
Artículo en Inglés | MEDLINE | ID: mdl-27621150

RESUMEN

AIM: To evaluate safety, tolerability and pharmacokinetics of oral PF-05190457, an oral ghrelin receptor inverse agonist, in healthy adults. METHODS: Single (SAD) and multiple ascending dose (MAD) studies were randomised, placebo-controlled, double-blind studies. Thirty-five healthy men (age 38.2 ± 10.4 years; body mass index 24.8 ± 3.1 kg m-2 [mean ± standard deviation]) received ≥1 dose (2, 10, 40 [divided], 50, 100, 150, and 300 [single or divided] mg) of PF-05190457 and/or placebo in the SAD. In the MAD study, 35 healthy men (age 39.7 ± 10.1 years; body mass index 25.9 ± 3.3 kg m-2 ) received ≥1 dose (2, 10, 40 and 100 mg twice daily) of PF-05190457 and/or placebo daily for 2 weeks. RESULTS: PF-05190457 absorption was rapid with a Tmax of 0.5-3 hours and a half-life between 8.2-9.8 hours. PF-05190457 dose-dependently blocked ghrelin (1 pmol kg-1  min-1 )-induced growth hormone (GH) release with (mean [90% confidence interval]) 77% [63-85%] inhibition at 100 mg. PF-05190457 (150 mg) delayed gastric emptying lag time by 30% [7-58%] and half emptying time by 20% [7-35%] with a corresponding decrease in postprandial glucose by 9 mg dL-1 . The most frequent adverse event reported by 30 subjects at doses ≥50 mg was somnolence. PF-05190457 plasma concentrations also increased heart rate up to 13.4 [4.8-58.2] beats min-1 and, similar to the effect on glucose and ghrelin-induced GH, was lost within 2 weeks. CONCLUSIONS: PF-05190457 is a well-tolerated first-in-class ghrelin receptor inverse agonist with acceptable pharmacokinetics for oral daily dosing. Blocking ghrelin receptors inhibits ghrelin-induced GH, and increases heart rate, effects that underwent tachyphylaxis with chronic dosing. PF-051940457 has the potential to treat centrally-acting disorders such as insomnia.


Asunto(s)
Azetidinas/administración & dosificación , Agonismo Inverso de Drogas , Receptores de Ghrelina/agonistas , Compuestos de Espiro/administración & dosificación , Administración Oral , Adulto , Azetidinas/farmacocinética , Azetidinas/farmacología , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Semivida , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Compuestos de Espiro/farmacocinética , Compuestos de Espiro/farmacología
8.
Contemp Clin Trials ; 134: 107352, 2023 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-37802221

RESUMEN

Non-alcoholic fatty liver disease (NAFLD) is the liver manifestation of the metabolic syndrome with global prevalence reaching epidemic levels. Despite the high disease burden in the population only a small proportion of those with NAFLD will develop progressive liver disease, for which there is currently no approved pharmacotherapy. Identifying those who are at risk of progressive NAFLD currently requires a liver biopsy which is problematic. Firstly, liver biopsy is invasive and therefore not appropriate for use in a condition like NAFLD that affects a large proportion of the population. Secondly, biopsy is limited by sampling and observer dependent variability which can lead to misclassification of disease severity. Non-invasive biomarkers are therefore needed to replace liver biopsy in the assessment of NAFLD. Our study addresses this unmet need. The LITMUS Imaging Study is a prospectively recruited multi-centre cohort study evaluating magnetic resonance imaging and elastography, and ultrasound elastography against liver histology as the reference standard. Imaging biomarkers and biopsy are acquired within a 100-day window. The study employs standardised processes for imaging data collection and analysis as well as a real time central monitoring and quality control process for all the data submitted for analysis. It is anticipated that the high-quality data generated from this study will underpin changes in clinical practice for the benefit of people with NAFLD. Study Registration: clinicaltrials.gov: NCT05479721.


Asunto(s)
Enfermedad del Hígado Graso no Alcohólico , Humanos , Enfermedad del Hígado Graso no Alcohólico/diagnóstico por imagen , Enfermedad del Hígado Graso no Alcohólico/patología , Estudios de Cohortes , Hígado/diagnóstico por imagen , Hígado/patología , Cirrosis Hepática/diagnóstico por imagen , Cirrosis Hepática/patología , Imagen por Resonancia Magnética/métodos , Biomarcadores
9.
Nat Med ; 27(10): 1836-1848, 2021 10.
Artículo en Inglés | MEDLINE | ID: mdl-34635855

RESUMEN

Alterations in lipid metabolism might contribute to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). However, no pharmacological agents are currently approved in the United States or the European Union for the treatment of NAFLD. Two parallel phase 2a studies investigated the effects of liver-directed ACC1/2 inhibition in adults with NAFLD. The first study ( NCT03248882 ) examined the effects of monotherapy with a novel ACC1/2 inhibitor, PF-05221304 (2, 10, 25 and 50 mg once daily (QD)), versus placebo at 16 weeks of treatment; the second study ( NCT03776175 ) investigated the effects of PF-05221304 (15 mg twice daily (BID)) co-administered with a DGAT2 inhibitor, PF-06865571 (300 mg BID), versus placebo after 6 weeks of treatment. The primary endpoint in both studies was percent change from baseline in liver fat assessed by magnetic resonance imaging-proton density fat fraction. Dose-dependent reductions in liver fat reached 50-65% with PF-05221304 monotherapy doses ≥10 mg QD; least squares mean (LSM) 80% confidence interval (CI) was -7.2 (-13.9, 0.0), -17.1 (-22.7, -11.1), -49.9 (-53.3, -46.2), -55.9 (-59.0, -52.4) and -64.8 (-67.5, -62.0) with 16 weeks placebo and PF-05221304 2, 10, 25 and 50 mg QD, respectively. The overall incidence of adverse events (AEs) did not increase with increasing PF-05221304 dose, except for a dose-dependent elevation in serum triglycerides (a known consequence of hepatic acetyl-coenzyme A carboxylase (ACC) inhibition) in 23/305 (8%) patients, leading to withdrawal in 13/305 (4%), and a dose-dependent elevation in other serum lipids. Co-administration of PF-05221304 and PF-06865571 lowered liver fat compared to placebo (placebo-adjusted LSM (90% CI) -44.6% (-54.8, -32.2)). Placebo-adjusted LSM (90% CI) reduction in liver fat was -44.5% (-55.0, -31.7) and -35.4% (-47.4, -20.7) after 6 weeks with PF-05221304 or PF-06865571 alone. AEs were reported for 10/28 (36%) patients after co-administered PF-05221304 and PF-06865571, with no discontinuations due to AEs, and the ACC inhibitor-mediated effect on serum triglycerides was mitigated, suggesting that PF-05221304 and PF-06865571 co-administration has the potential to address some of the limitations of ACC inhibition alone.


Asunto(s)
Acetil-CoA Carboxilasa/antagonistas & inhibidores , Diacilglicerol O-Acetiltransferasa/antagonistas & inhibidores , Inhibidores Enzimáticos/administración & dosificación , Hígado/enzimología , Enfermedad del Hígado Graso no Alcohólico/tratamiento farmacológico , Acetil-CoA Carboxilasa/genética , Diacilglicerol O-Acetiltransferasa/genética , Método Doble Ciego , Sinergismo Farmacológico , Inhibidores Enzimáticos/efectos adversos , Femenino , Humanos , Metabolismo de los Lípidos/efectos de los fármacos , Hígado/efectos de los fármacos , Hígado/ultraestructura , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Enfermedad del Hígado Graso no Alcohólico/genética , Enfermedad del Hígado Graso no Alcohólico/patología , Placebos
10.
Ultrasound Med Biol ; 46(12): 3379-3392, 2020 12.
Artículo en Inglés | MEDLINE | ID: mdl-32917469

RESUMEN

Fifty years of research on the nature of backscatter from tissues has resulted in a number of promising diagnostic parameters. We recently introduced two analyses tied directly to the biophysics of ultrasound scattering: the H-scan, based on a matched filter approach to distinguishing scattering transfer functions, and the Burr distribution for quantification of speckle patterns. Together, these analyses can produce at least five parameters that are directly linked to the mathematics of ultrasound in tissue. These have been measured in vivo in 35 rat livers under normal conditions and after exposure to compounds that induce inflammation, fibrosis, and steatosis in varying combinations. A classification technique, the support vector machine, is employed to determine clusters of the five parameters that are signatures of the different liver conditions. With the multiparametric measurement approach and determination of clusters, the different types of liver pathology can be discriminated with 94.6% accuracy.


Asunto(s)
Hepatopatías/diagnóstico por imagen , Hígado/diagnóstico por imagen , Máquina de Vectores de Soporte , Animales , Masculino , Ratas , Ratas Sprague-Dawley , Ultrasonografía/métodos
11.
Obesity (Silver Spring) ; 26(11): 1785-1795, 2018 11.
Artículo en Inglés | MEDLINE | ID: mdl-29785727

RESUMEN

OBJECTIVE: This study aimed to investigate the value of imaging-based multivariable body composition profiling by describing its association with coronary heart disease (CHD), type 2 diabetes (T2D), and metabolic health on individual and population levels. METHODS: The first 6,021 participants scanned by UK Biobank were included. Body composition profiles (BCPs) were calculated, including abdominal subcutaneous adipose tissue, visceral adipose tissue (VAT), thigh muscle volume, liver fat, and muscle fat infiltration (MFI), determined using magnetic resonance imaging. Associations between BCP and metabolic status were investigated using matching procedures and multivariable statistical modeling. RESULTS: Matched control analysis showed that higher VAT and MFI were associated with CHD and T2D (P < 0.001). Higher liver fat was associated with T2D (P < 0.001) and lower liver fat with CHD (P < 0.05), matching on VAT. Multivariable modeling showed that lower VAT and MFI were associated with metabolic health (P < 0.001), and liver fat was nonsignificant. Associations remained significant adjusting for sex, age, BMI, alcohol, smoking, and physical activity. CONCLUSIONS: Body composition profiling enabled an intuitive visualization of body composition and showed the complexity of associations between fat distribution and metabolic status, stressing the importance of a multivariable approach. Different diseases were linked to different BCPs, which could not be described by a single fat compartment alone.


Asunto(s)
Bancos de Muestras Biológicas/normas , Composición Corporal/fisiología , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Reino Unido
12.
Ultrasound Med Biol ; 33(8): 1309-19, 2007 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-17467150

RESUMEN

Accurate measurement of structural features represented in medical images is important in clinical trials and patient diagnosis. A key factor for precision is spatial resolution, which in ultrasonic imaging is limited by transducer array arrangements, transmitting frequency, and data acquisition firmware. In this paper, a variation of pixel compounding is proposed to enhance ultrasound resolution using acquired cine loops. The technique operates on a sequence of ultrasound B-scan images acquired with random motion. Subpixel registration is estimated and a maximum a posteriori (MAP) approach with the shift information is used to reconstruct a high-resolution single image. A nonhomogeneous anisotropic diffusion algorithm follows from the estimation process and is implemented to enhance the high-resolution edges. Preliminary tests using simulations and phantom studies show promising results. Pixel compounding can be a powerful preprocessing tool to assure accurate segmentation, measurement, and analysis of ultrasound images.


Asunto(s)
Arterias Carótidas/diagnóstico por imagen , Ecoencefalografía/métodos , Procesamiento de Imagen Asistido por Computador/métodos , Algoritmos , Anisotropía , Arterias Carótidas/patología , Enfermedades de las Arterias Carótidas/diagnóstico por imagen , Humanos , Fantasmas de Imagen , Transductores , Túnica Íntima/diagnóstico por imagen , Túnica Íntima/patología , Túnica Media/diagnóstico por imagen , Túnica Media/patología
13.
Ultrasound Med Biol ; 37(6): 909-21, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21531499

RESUMEN

We report a comparison between tumor perfusion estimates acquired using contrast-enhanced MRI and motion-corrected contrast-enhanced ultrasound before and after treatment with AG-028262, a potent vascular endothelial growth factor receptor tyrosine kinase inhibitor. Antiangiogenic activity was determined by assessing weekly ultrasound and MRI images of rats with bilateral hind flank mammary adenocarcinomas before and after treatment with AG-028262. Images were acquired with a spoiled gradient, 1.5 T magnetic resonance sequence and a destruction-replenishment ultrasound protocol. For ultrasound, a time to 80% contrast replenishment was calculated for each tumor voxel; for MR imaging, a measure of local flow rate was estimated from a linear fit of minimum to maximum intensities. AG-028262 significantly decreased tumor growth and increased the time required to replenish tumor voxels with an ultrasound contrast agent from 2.66 to 4.54 s and to fill with an MR contrast agent from 29.5 to 50.8 s. Measures of flow rate derived from MRI and ultrasound demonstrated a positive linear correlation of r2 = 0.86.


Asunto(s)
Inhibidores de la Angiogénesis/administración & dosificación , Imagen de Difusión por Resonancia Magnética/métodos , Neoplasias Mamarias Experimentales/diagnóstico , Neoplasias Mamarias Experimentales/tratamiento farmacológico , Neovascularización Patológica/diagnóstico , Neovascularización Patológica/tratamiento farmacológico , Ultrasonografía/métodos , Adenocarcinoma/complicaciones , Adenocarcinoma/diagnóstico , Adenocarcinoma/tratamiento farmacológico , Animales , Línea Celular Tumoral , Femenino , Masculino , Neoplasias Mamarias Experimentales/complicaciones , Neovascularización Patológica/etiología , Ratas , Ratas Endogámicas F344 , Receptores de Factores de Crecimiento Endotelial Vascular/efectos de los fármacos , Resultado del Tratamiento
14.
Acad Radiol ; 16(6): 700-7, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19362025

RESUMEN

RATIONALE AND OBJECTIVES: Inhaled hyperpolarized (3)He magnetic resonance (MR) imaging has been used to measure alveolar size in patients with emphysema. The aim of this study was to test the hypothesis that (3)He MR images could be used to develop a biomarker of emphysema progression. MATERIALS AND METHODS: Twelve healthy controls and 18 patients with emphysema (eight current smokers, 10 ex-smokers) were imaged at baseline and 6 and 12 months. An additional nine subjects with alpha-1 antitrypsin deficiency (four with emphysema, six without symptoms) were also imaged at baseline and at 6 months. Each subject was imaged at two lung volumes: functional residual capacity (FRC) and FRC plus 15% of total lung capacity. Means and standard deviations of apparent diffusion coefficients (ADCs) were calculated from coronal images of the entire lung and correlated with pulmonary function test results. The lacunarity hypothesis was tested and calculated from the data using a range of 2 x 2 x 2 to 6 x 6 x 6 voxels, and the average was calculated. RESULTS: There was no change in the mean ADC at either lung volume in any subject over the 6- or 12-month period. FRC and residual volume increased over the 12 months, suggesting air trapping. The lacunarity of images collected at FRC increased at 6 and 12 months in smokers only (P = .063 and P = .023, respectively). CONCLUSIONS: The mean ADC calculated from MR images of the lungs with helium was not sufficiently sensitive to detect changes over a 12-month period. However, lacunarity captured more of the spatial information in the images and detected emphysema progress in the smokers.


Asunto(s)
Enfisema/diagnóstico , Helio/administración & dosificación , Interpretación de Imagen Asistida por Computador/métodos , Imagen por Resonancia Magnética/métodos , Administración por Inhalación , Adulto , Anciano , Medios de Contraste/administración & dosificación , Femenino , Humanos , Isótopos/administración & dosificación , Masculino , Persona de Mediana Edad , Reproducibilidad de los Resultados , Sensibilidad y Especificidad
15.
Cancer Biol Ther ; 8(9): 856-65, 2009 May.
Artículo en Inglés | MEDLINE | ID: mdl-19458500

RESUMEN

EXPERIMENTAL DESIGN: To investigate the antitumor effect of sunitinib and FAK/Pyk2 tyrosine kinase inhibitor (PF-562,271)combination therapy in vivo, utilizing human hepatocellular carcinoma (HCC) cells Huh7.5. Nude rats were inoculated subcutaneously with Huh7.5 hepatoma cells. Dosing for Phase 1 was initiated on day 5 post tumor inoculations with Vehicle(Group 1), sunitinib (25 mg/kg/day; Group 2) and sunitinib plus PF-562,271 combination (15 mg/kg/day; Group 3). Phase 2 of the study started on day 26, and each of the three original groups was divided in two subgroups; half of the rats remained on original therapy (Groups 1A and 2A) with the exception of Group 3A that was euthanized after Phase 1. The other half of the rats were switched to sunitinib and PF-562,271 combination (Group 1B) or vehicle (Groups 2B and 3B). Tumor volume and weight, serum alpha feto-protein (AFP), contrast-enhanced ultrasound imaging (CEUS) and tumor histology were used to evaluate effects of treatment on tumor growth. RESULTS: The results from this study indicate that the combination of sunitinib and PF-562,271 TKI has the potential to target different aspects of angiogenesis and tumor aggressiveness and may have significantly greater effect than relevant single agent, blocking not only tumor growth, but also impacting the ability of the tumor to recover upon withdrawal of the therapy.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Carcinoma Hepatocelular/tratamiento farmacológico , Indoles/farmacología , Neoplasias Hepáticas/tratamiento farmacológico , Pirroles/farmacología , Sulfonamidas/farmacología , Animales , Carcinoma Hepatocelular/patología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Quinasa 2 de Adhesión Focal/antagonistas & inhibidores , Humanos , Indoles/administración & dosificación , Neoplasias Hepáticas/patología , Masculino , Inhibidores de Proteínas Quinasas/administración & dosificación , Pirroles/administración & dosificación , Ratas , Ratas Desnudas , Sulfonamidas/administración & dosificación , Sunitinib , Ensayos Antitumor por Modelo de Xenoinjerto
16.
AJR Am J Roentgenol ; 180(1): 215-22, 2003 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-12490508

RESUMEN

OBJECTIVE: The objective of our study was to evaluate the color Doppler sonographic effect known as twinkling artifact. MATERIALS AND METHODS: Struvite (ammonium magnesium phosphate) stone fragments, wire mesh, and a flat surface were scanned in a water bath with a sonography scanner using a high-frequency linear array probe fixed in a ring clamp. Pulse repetition frequency, color-write priority, gray-scale gain, and spectral Doppler gain were varied. Color and spectral Doppler modes were used. RESULTS: Twinkling artifact and spectral broadening were seen most intensely behind struvite stone fragments, and both were seen more strongly behind wire mesh with greater surface roughness than behind wire mesh with less surface roughness or a flat surface. The appearance of the twinkling artifact is highly dependent on machine settings. System noise measured on a flat surface generates a band-limited Doppler shift on spectral displays with a mean frequency shift of 0 Hz and a mean (+/- SD) absolute fluctuation of 86 +/- 10 Hz over a pulse repetition frequency range of 1250-10,000 Hz. Rough surfaces increase the spectral bandwidth. CONCLUSION: The appearance of the twinkling artifact is highly dependent on machine settings and is likely generated by a narrow-band, intrinsic machine noise called phase (or clock) jitter. Surface roughness secondarily broadens the noise spectrum. With a strongly reflecting, rough surface such as a renal stone, the high amplitude, broadband signal appears as random motion in color Doppler sonography. Understanding of the twinkling artifact may result in better use of its clinical appearance.


Asunto(s)
Artefactos , Ultrasonografía Doppler en Color , Cálculos Urinarios/diagnóstico por imagen , Humanos , Compuestos de Magnesio , Fantasmas de Imagen , Fosfatos , Estruvita , Ultrasonografía Doppler en Color/instrumentación , Cálculos Urinarios/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA